HSHyeong-Won Seo

Hyeong-Won Seo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hyeong-Won Seo has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Chawetsan Namwat

    Affiliation Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand

    1 shared publication
  • Chulwoo Rhee

    Affiliation International Vaccine Institute, Seoul, Republic of Korea

    1 shared publication
  • Deok-Ryun Kim

    Affiliation International Vaccine Institute, Seoul, Republic of Korea

    1 shared publication
  • Elizabeth R. Unger

    Affiliation Chronic Viral Diseases Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, United States of America

    1 shared publication
  • Hyeon Seon Ahn

    Affiliation International Vaccine Institute, Seoul, Republic of Korea

    1 shared publication
  • Jean Louis Excler

    Affiliation International Vaccine Institute, Seoul, Republic of Korea

    1 shared publication

Latest Publications

  • Open Access

    A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand

    by Suchada Jiamsiri, Chulwoo Rhee, Hyeon Seon Ahn, Nimesh Poudyal, Hyeong-Won Seo, Worrawan Klinsupa, Pornjarim Nilyanimit, Nakorn Premsri, Chawetsan Namwat, Sompong Vonpunsawad, et al.

    Human papillomavirus (HPV) is a common infection principally spread through sexual activity. Most HPV infections are asymptomatic and resolve spontaneously. However, persistent infection may progress to cervical cancer. Highly efficacious HPV vaccines have been available since 2006, yet uptake into national programs has been slow in part due to cost. WHO guidelines call for a two-dose (0,6 month) schedule for girls 9–14 years of age. Post-hoc analyses of randomized trials have found high vaccine effectiveness following a single dose of vaccine. In order to provide additional data on the potential impact of single dose HPV vaccination in a real-world setting, we are conducting an effectiveness study among Thai schoolgirls. This is an observational study of a single dose (SD) or two doses (2D) of the bivalent HPV vaccine CERVARIX® (GlaxoSmithKline plc.) administered in a school-based program to 8–9,000 Grade 8 female students in two provinces of Thailand beginning in 2018; one province is assigned the SD, and the other the standard 2D regimen. The reduction in HPV vaccine-type prevalence will be assessed in each province two and four years after vaccination by comparing HPV prevalence in urine samples obtained through cross-sectional surveys of the immunized grade cohort as they age and compared to a historical “baseline” HPV prevalence of same age students.